Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
284lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
9 lessons
7mPolicyAdvanced
Why Emideltide (DSIP) Was the Only Peptide the Panel Did Not Recommend
The panel backed six peptide nominations but not Emideltide. Here is why evidence and identity questions mattered, and what the result means for people following sleep peptides.
7mResearchAdvanced
MOTS-c's 503A Recommendation: What Changed and What Did Not
MOTS-c now has a favorable advisory recommendation. It still does not have FDA drug approval or an open 503A compounding path.
7mPolicyAdvanced
After the PCAC Votes: Category 1 Interim Access vs Waiting for Rulemaking
PCAC recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for 503A compounding. The unresolved fight is what happens while FDA completes rulemaking.
7mPolicyAdvanced
Semax After the PCAC Recommendation: Access, Evidence, and What to Watch
The favorable Semax vote moved its compounding nomination forward, but the narrow result exposed unresolved questions about evidence, characterization, and US clinical use.
9mPolicyAdvanced
FDA's July 23 Peptide Panel Backed BPC-157, KPV, and TB-500. Here Is What Happens Next.
The FDA's peptide panel made its first moves on BPC-157, KPV, and TB-500. The vote matters, but the real story is what it changes next and what still has to happen before compounding pharmacies see any relief.
8mPolicyAdvanced
FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026
The FDA's April 2026 announcement removed 12 peptides from Category 2 restrictions — the biggest regulatory shift in years. BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax are among those affected. Here's what it actually means for your access.
10mPolicyAdvanced
FDA Schedules July 2026 Advisory Panel to Reclassify 12 Peptides — What It Means for BPC-157, MOTS-C, and GHK-Cu
An FDA advisory panel scheduled for July 2026 could reshape access to 12 peptides — including BPC-157, MOTS-C, and GHK-Cu. Here's what's on the table, what reclassification would mean in practice, and how to prepare for either outcome.
9mPolicyAdvanced
BPC-157 and the 2026 Regulatory Shift: What the HHS Category 1 Push Means for Peptide Access
After years of regulatory limbo, BPC-157 is at the center of a major policy battle. The RFK Jr.-led HHS push to reclassify it as Category 1 could restore legal compounding access—or the FDA could dig in. Here's where things stand.
9mPolicyAdvanced
FDA's Regulatory Shift on Compounded Peptides: What the 2026 Policy Signals Mean for You
A potential FDA regulatory shift on 14 compounded peptides — including BPC-157 and TB-500 — could reshape who gets access to peptide therapy and how. Here's what the current signals actually mean.
Also available at /blog for legacy links.